Episode Details

AOTI Inc. CEO Mike Griffiths joined Steve Darling from Proactive to highlight key findings from a newly published multicentre retrospective cohort study in the Journal of Vascular Surgery–Vascular Insights, evaluating the effectiveness of the company’s Topical Wound Oxygen (TWO) therapy in treating chronic lower extremity wounds. Griffiths explained that the study demonstrated a high rate of complete and durable healing using AOTI’s intermittent TWO2® therapy as an adjunct to standard of care. The therapy was applied to hard-to-heal wounds that had previously failed to respond to other advanced treatments for an average of seven months, underscoring the complexity of the patient population. The large-scale study included 3,126 patients across a wide range of wound types, including diabetic foot ulcers, venous leg ulcers, arterial ulcers, and atypical wounds. The findings build on prior randomized clinical trials and real-world evidence supporting the therapy’s effectiveness, particularly in diabetic foot ulcers. Results showed that 64.8% of patients (2,027 individuals) achieved complete wound healing, with an average healing time of 4.2 months—despite wounds having persisted for an average of seven months prior to treatment. Notably, the durability of healing was strong, with only 2.7% of patients requiring retreatment due to recurrence over an average follow-up period of nearly 14 months. Griffiths also highlighted meaningful reductions in serious complications. The study reported hospitalization rates of just 3.7% and amputation rates of 6.1%, both significantly lower than historical benchmarks for similar high-risk populations. These results further reinforce the growing body of clinical and real-world evidence supporting TWO2® therapy as an effective adjunctive treatment for chronic wounds, offering improved healing outcomes and reduced complications for patients with complex medical conditions. #proactiveinvestors #aoti #aim #topicalwoundoxygen #two2 #woundcare #Healthcare #MedTech #OxygenTherapy #DiabeticFootUlcer #ChronicWounds #MedicalResearch #PatientOutcomes #Innovation